NDA 214988 · Be Pharms
Dehydrated Alcohol
Dehydrated Alcohol · Intravenous
OrphanLast checked: Nov 20, 2026Latest source record: Oct 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Oct 23, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,532
244 Phase 3, 166 recruiting
FAERS reports
27,075
25,838 serious, 15,214 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- DEHYDRATED ALCOHOL · DEHYDRATED ALCOHOL 98% (5ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Dehydrated Alcohol" as an intervention, any sponsor and status, largest first.
Centro Neurológico de Pesquisa e Reabiitação, BrazilAcademic, hospital or other
NCT03147092 · 15,000 participants (planned) · Start Feb 1, 2018 · Primary completion Jun 30, 2020
Drug: Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,; Atenolol and 2 more · For: Hypertension; Blood Pressure
Boston UniversityAcademic, hospital or other
NCT02386592 · 9,410 participants · Start Sep 1, 2015 · Primary completion Apr 15, 2017
Drug: Chlorhexidine gluconate (CHG) · For: Neonatal Sepsis; Neonatal Mortality
Sites: Lusaka, Zambia
- Pre-operative Alcohol Skin Solutions in Fractured ExtremitiesPivotal-lookingCompleted
University of Maryland, BaltimoreAcademic, hospital or other
NCT03523962 · 8,485 participants · Start Aug 21, 2018 · Primary completion Mar 15, 2023
Drug: DuraPrep; ChloraPrep · For: Surgical Site Infection; Unplanned Fracture-Related Reoperation; Open Appendicular Fracture and 2 more
Sites: Irvine, California; Los Angeles, California; San Jose, California · 27 sites in all
- Coordinated Access for Addiction Recovery and Equity in VA Supportive HousingPivotal-lookingEnrolling by invitation
VA Office of Research and DevelopmentFederal agency
NCT07141394 · 7,908 participants (planned) · Start Sep 15, 2026 · Primary completion Sep 30, 2030
Drug: Medication for Addiction Treatment (MAT) · For: Homelessness; Substance Use Disorder (SUD)
Sites: West Los Angeles, California
- ROSSINI 2 - Reduction of Surgical Site Infection Using Several Novel InterventionsPivotal-lookingStatus unknown
University of BirminghamAcademic, hospital or other
NCT03838575 · 6,610 participants (planned) · Start Mar 1, 2019 · Primary completion May 2023
Drug: 2% alcoholic chlorhexidine skin prep (SKIN PREP) · For: Surgical Site Infection; Surgical Wound Infection; Surgery--Complications and 1 more
Sites: Birmingham, United Kingdom; Chester, United Kingdom
University of Alabama at BirminghamAcademic, hospital or other
NCT02938377 · 4,985 participants · Start Nov 6, 2017 · Primary completion Nov 1, 2022
Drug: Recommendation and Counseling for Alcohol Pharmacotherapy · For: HIV Positive; Alcohol Use
Sites: Birmingham, Alabama; Seattle, Washington
- Skip Prep of Vaginal Delivery to Prevent Puerperal / Perinatal Infection in Vaginal DeliveryPivotal-lookingStatus unknown
Seoul National University HospitalAcademic, hospital or other
NCT05122169 · 4,140 participants (planned) · Start Dec 2021 · Primary completion Dec 31, 2025
Drug: Povidone-Iodine; Chlorhexidine · For: Vaginal Delivery; Surgical Site Infection
- A Cluster-randomized Cross-over Trial Evaluating the Comparative Effectiveness of Three Skin Antiseptic InterventionsPivotal-lookingCompleted
University of MichiganAcademic, hospital or other
NCT01216761 · 3,879 participants · Start May 2008 · Primary completion Sep 2009
Drug: Iodine tincture; Chlorhexidine gluconate and 1 more · For: Bacteremia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- toxicity to various agents6,095
- completed suicide5,439
- drug abuse5,341
- overdose1,906
- death1,608
- intentional overdose1,554
- suicide attempt1,374
- cardio-respiratory arrest1,349
- somnolence959
- drug dependence932
- drug interaction907
- coma867
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 241 |
| 2005 | 262 |
| 2006 | 264 |
| 2007 | 415 |
| 2008 | 440 |
| 2009 | 474 |
| 2010 | 575 |
| 2011 | 516 |
| 2012 | 438 |
| 2013 | 520 |
| 2014 | 481 |
| 2015 | 531 |
| 2016 | 619 |
| 2017 | 2,140 |
| 2018 | 1,714 |
| 2019 | 2,118 |
| 2020 | 2,655 |
| 2021 | 1,650 |
| 2022 | 2,393 |
| 2023 | 2,567 |
| 2024 | 2,159 |
| 2025 | 2,074 |
| 2026 | 1,829 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Phase I trial of taxol given as a 3-hour infusion every 21 days.
Kris MG, O'Connell JP, Gralla RJ, et al. · Cancer Treat Rep 1986 · Clinical Trial, Research Support, U.S. Gov't, P.H.S.
- Cough and wheezing from beclomethasone dipropionate aerosol are absent after triamcinolone acetonide.
Shim CS, Williams MH · Ann Intern Med 1987 · Clinical Trial, Comparative Study
- A multicenter phase II randomized study of Cremophor-free polymeric nanoparticle formulation of paclitaxel in women with locally advanced and/or metastatic breast cancer after failure of anthracycline.
Ranade AA, Bapsy PP, Nag S, et al. · Asia Pac J Clin Oncol 2013 · Clinical Trial, Phase II, Comparative Study
Sponsor: Be Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.